PDA

View Full Version : Osteoporosis and bisphosphonates


Welcome to the Active Low-Carber Forums

Support for Atkins diet, Protein Power, Neanderthin (Paleo Diet), CAD/CALP, Dr. Bernstein Diabetes Solution and any other healthy low-carb diet or plan, all are welcome in our lowcarb community. Forget starvation and fad diets -- join the healthy eating crowd! You may register by clicking here, it's free!



Ironjustic
Thu, May-10-07, 17:15
Osteoporosis Treatment -- Without Estrogen Libraries Medical
News Keywords POSTMENOPAUSAL, OSTEOPOROSIS Contact Information

Available for logged-in reporters only Description

A class of drugs called bisphosphonates has become the new
mainstay treatment for postmenopausal women diagnosed with
osteoporosis in the post-hormone-replacement era. Taking just
one pill a week, or even one a month, may prevent, slow or
stop the breakdown and progress of this bone-thinning
condition, according to the May issue of Mayo Clinic Women's
HealthSource.

Newswise - A class of drugs called bisphosphonates has become
the new mainstay treatment for postmenopausal women diagnosed
with osteoporosis in the post-hormone-replacement era. Taking
just one pill a week, or even one a month, may prevent, slow
or stop the breakdown and progress of this bone-thinning
condition, according to the May issue of Mayo Clinic Women's
HealthSource.

An estimated 10 million Americans, mostly women, have
osteoporosis, where bones become weak and highly prone to
fractures. Millions more have low bone density (osteopenia),
which can increase the risk of fractures.

Bone -- a living tissue -- is constantly remodeling, with old
bone breaking down and new bone replacing it. Bisphosphonates
work by slowing the breakdown and reabsorption of old bone, an
ongoing process that accelerates as estrogen levels fall
during the first few years after menopause. By slowing the
process, bisphosphonates help preserve bone density and reduce
the risk of fractures.

Estrogen once was commonly prescribed to reduce bone loss. But
when the landmark Women's Health Initiative Study, released in
2002, showed that long-term estrogen use increased the risk of
breast cancer, heart attacks, strokes and blood clots, hormone
therapy fell out of favor.

Bisphosphonates have filled the void and perform as well as
estrogen in preventing bone loss. Bisphosphonates available to
treat osteoporosis include alendronate (Fosamax), ibandronate
(Boniva) and risedronate (Actonel).

Patients should talk with a doctor about the best ways to
prevent and treat osteoporosis. Bisphosphonates have
potential side effects, most commonly heartburn and abdominal
pain caused by irritation of the esophagus or stomach. Even
when taking medications, patients should take steps to
protect bones, including consuming adequate calcium and
vitamin D; engaging in regular weight-bearing exercise such
as walking and weight training; and avoiding smoking and
excessive use of alcohol.

--------------------------------------------------------------
--------------=
-----

=A9 2007 Newswise. All Rights Reserved. ----------------------
------------------------------------------------------=
-----

http://tinyurl.com/4ustm

Bisphosphonates

Bisphosphonates are a family of drugs used to prevent and
treat osteoporosis. There are three bisphosphonates currently
approved for use in Canada: alendronate (Fosamax =AE),
etidronate (Didrocal =AE) and risedronate (Actonel =AE).

--------------------------------------------------------------
--------------= =AD----------

<<snip>> Bisphosphonates have antioxidant properties as iron
chelators <<snip>>

Antioxidant effect of bisphosphonates and simvastatin on
chondrocyte lipid peroxidation. Dombrecht EJ, De Tollenaere
CB, Aerts K, Cos P, Schuerwegh AJ, Bridts CH, Van Offel JF,
Ebo DG, Stevens WJ, De Clerck LS Biochem Biophys Res Commun.
2006 Jul 28;

The objective of this study was to evaluate the effect of
bisphosphonates (BPs) and simvastatin on chondrocyte lipid
peroxidation. For this purpose, a flow cytometrical method
using C11-BODIPY(581/591) was developed to detect
hydroperoxide-induced lipid peroxidation in chondrocytes.
Tertiary butylhydroperoxide (t-BHP) induced a time and
concentration dependent increase in chondrocyte lipid
peroxidation. Addition of a Fe(2+)/EDTA complex to t-BHP or
hydrogen peroxide (H(2)O(2)) clearly enhanced lipid
peroxidation. The lipophilic simvastatin demonstrated a small
inhibition in the chondrocyte lipid peroxidation. None of
three tested BPs (clodronate, pamidronate, and risedronate)
had an effect on chondrocyte lipid peroxidation induced by
t-BHP. However, when Fe(2+)/EDTA complex was added to t-BHP or
H(2)O(2), BPs inhibited the lipid peroxidation process varying
from 25% to 58%. This study demonstrates that BPs have
antioxidant properties as iron chelators, thereby inhibiting
the chondrocyte lipid peroxidation. These findings add
evidence to the therapeutic potential of bisphosphonates and
statins in rheumatoid arthritis.

--------------------------------------------------------------
--------------= =AD----------

Age-associated Iron Accumulation in Bone: Implications for
Postmenopausal Osteoporosis and a New Target for Prevention
and Treatment by Chelation. Liu G, Men P, Kenner GH, Miller SC
Biometals. 2006 May 11;

Iron accumulation in tissues is believed to be a
characteristic of aged

humans and a risk factor for some chronic diseases. However,
it is not known whether age-associated iron accumulation is
part of the pathogenesis of postmenopausal osteoporosis that
affects approximately one out three women worldwide. Here, we
confirmed that this accumulation of iron was associated with
osteopenia in ovariectomized (OVX) rats (a model of peri- and
postmenopausal osteoporosis due to estrogen deficiency). To
further investigate whether the increased iron

level plays a causal role in the onset of bone loss, we
treated OVX rats with an orally active and bone targeted
chelator that prevented iron accumulation in their skeletal
tissues. The results showed that this treatment mitigated the
loss of bone mass and the deterioration of

bone micro-architecture. We also found that one possible
mechanism of the protective action of iron chelation was to
significantly reduce bone resorption. Thus, these findings
provide a novel target and a potentially useful therapeutic
strategy for the prevention and treatment of postmenopausal
osteoporosis and perhaps other age- related diseases.

Who loves ya. Tom

Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com

Man Is A Herbivore! http://tinyurl.com/a3cc3

DEAD PEOPLE WALKING http://tinyurl.com/zk9fk

Juhana Har
Thu, May-10-07, 17:15
ironjustice@aol.com wrote:

: Age-associated Iron Accumulation in Bone: Implications for
: Postmenopausal Osteoporosis and a New Target for Prevention
: and Treatment by Chelation. Liu G, Men P, Kenner GH, Miller
: SC Biometals. 2006 May 11;
:
: Iron accumulation in tissues is believed to be a
: characteristic of aged
:
:
: humans and a risk factor for some chronic diseases. However,
: it is not known whether age-associated iron accumulation is
: part of the pathogenesis of postmenopausal osteoporosis that
: affects approximately one out three women worldwide. Here,
: we confirmed that this accumulation of iron was associated
: with osteopenia in ovariectomized (OVX) rats (a model of
: peri- and postmenopausal osteoporosis due to estrogen
: deficiency). To further investigate whether the increased
: iron level plays a causal role in the onset of bone loss, we
: treated OVX rats with an orally active and bone targeted
: chelator that prevented iron accumulation in their skeletal
: tissues. The results showed that this treatment mitigated
: the loss of bone mass and the deterioration of bone
: micro-architecture. We also found that one possible
: mechanism of the protective action of iron chelation was to
: significantly reduce bone resorption. Thus, these findings
: provide a novel target and a potentially useful therapeutic
: strategy for the prevention and treatment of postmenopausal
: osteoporosis and perhaps other age- related diseases.

Iron restriction has a negative effect on bone:

http://tinyurl.com/2clp9n

http://tinyurl.com/2zyzrq

--
Juhana

Ironjustic
Mon, May-14-07, 17:15
>>On May 13, 7:54 am, iceman458...@yahoo.com wrote:
This makes me wonder if any naturally occurring substitutes
exist for bisphosphonates which someone can just pop and gain
the same benefits. Is this just Phosphate in a fancy
wrapping?<<

If you notice the .. phosphate groups / myo-inositol
hexaphosphate seem to be SUPERIOR to the bisphosponate ..
etidronate.

<<snip>> myo-inositol hexaphosphate acts as an inhibitor of
calcium salt crystallization <<snip>>

Life Sci. 2004 May 21;75(1):11-9. Links Dietary myo-inositol
hexaphosphate prevents dystrophic calcifications in soft
tissues: a pilot study in Wistar rats.Grases F, Perello J,
Prieto RM, Simonet BM, Torres JJ. Laboratory of Renal
Lithiasis Research, Institute of Health Sciences (IUNICS),
University of Balearic Islands, Ctra. Valldemossa Km 7.5,
07071, Palma de Mallorca, Spain. fgrases@uib.es

Myo-inositol hexaphosphate (InsP6) is an abundant component of
plant seeds. It is also found in significant levels in blood
and mammalian tissues, but they are totally dependent on their
dietary intake. In the present paper, we describe studies on
the effect of InsP6 on a model of dystrophic calcification,
which was chemically induced by subcutaneous injection of a
0.1% KMnO4 solution. Male Wistar rats were randomly divided
into four groups for treatment over 31 days. A: animals
consuming a purified diet in which InsP6 was absent but to
which 1% of InsP6 (as sodium salt) was added. In this group,
the InsP6 plasma levels (0.393 +/- 0.013 microM) were similar
to those observed in rats consuming a standard diet. B:
animals consuming only the purified diet in which InsP6 was
absent. In this case the InsP6 plasma levels decreased (0.026
+/- 0.006 microM); C: animals consuming the same purified diet
as group B but received daily subcutaneous injections of 50
microg kg(-1) etidronate during the last 14 days. In this case
the InsP6 plasma levels were also very low (0.025 +/- 0.007
microM); D: animals consuming the same diet as group B but a
6% of carob germ (InsP6 rich product) was added. The InsP6
plasma levels (.363 +/- 0.035 microM) were also similar to
those observed in rats consuming a standard diet. After 21
days plaque formation was induced. Calcification plaques were
allowed to proceed for 10 days, after which the plaque
material present was excised, dried and weighed. It was found
that the presence of myo-inositol hexaphosphate (phytate) in
plasma at normal concentrations (0.3-0.4 microM) clearly
inhibited the development of dystrophic calcifications in soft
tissues. These results demonstrates that myo-inositol
hexaphosphate acts as an inhibitor of calcium salt
crystallization.

PMID: 15102518 [PubMed - indexed for MEDLINE]

Who loves ya. Tom

Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com

Man Is A Herbivore! http://tinyurl.com/a3cc3

DEAD PEOPLE WALKING http://tinyurl.com/zk9fk

iceman4584
Thu, May-24-07, 06:15
Phytates. Isn't that supposed to be those chemicals present in
seeds that we are supposed to get rid of, by soaking the seeds
or the beans before cooking them so that no more phytates
remain and there will be no interference in absorbtion of
nutrients in the gut after the phytates are gone? Phytates
block absorbtion of minerals and nutrients. I thought phytates
were the bad guys, oats have a huge amount of them.